Report : South and Central America Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ( Voriconazole, Liposomal, Amphotericin B, Systemic Oral Azoles, Topical, Antifungal Agents, Others ); Application ( Chronic, Pulmonary Aspergillosis (CPA), Allergic, Bronchopulmonary Aspergillosis (ABPA), Gastrointestinal Candidasis, Genitourinary Tract Candidasis, Others ), and Country
According to the latest study on ‘South and Central America Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the South and Central America systemic aspergillosis and systemic candidasis market was valued at US$ 308.09 million in 2019 and is projected to reach US$ 395.06 million by 2027; it is expected to grow at a CAGR of 3.2% during 2020–2027. The report highlights the trends prevailing in the South and Central America systemic aspergillosis and systemic candidasis market and the factors driving the market along with those that act as deterrents to its growth.
Based on type, the systemic aspergillosis and systemic candidasis market is segmented voriconazole, liposomal, amphotericin B, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment accounted for the largest share of the South and Central America systemic aspergillosis and systemic candidasis market. The growth of the segment attributes to the to rise in prevalence of fungal diseases is among the primary factors contributing to the dominance of the segment in the South and Central America systemic aspergillosis and systemic candidasis market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the South and Central America region. Systemic aspergillosis and systemic candidiasis are the types of fungal infections. Molds cause the aspergillosis infection and majorly affects the respiratory tract of an individual. In addition it is a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable leading to death, severe chronic illness, or blindness. For instance, Candida Auris is a fungus that causes a severe health threat. C. Auris causes severe illness in hospitalized patients in several countries, including the United States. Patients can remain colonized with C. Auris for a long time, and C. Auris can persist on surfaces in healthcare environments. This can result in the spread of C. Auris between patients in healthcare facilities. Thus, this can be a hospital-acquired infection. Candida Auris's emergence is considered one of the most severe problems associated with nosocomial transmission and infection control practices in the hospital environment. Furthermore, countermeasures to limit fungal infections in intensive care units (ICUs) continue to be reported, with a tendency to an endemic pattern. This reflects the ability of C. auris to persist in a clinical environment, enabling its transmission within an acute care setting. Other than Candida species, C. auris can colonize different anatomical sites (e.g., skin, axilla, rectum, stool) and contaminate the hospital equipment and surfaces, creating a vicious cycle spreading, acquisition, and infection, particularly in ICUs. Additionally, according to the NCBI report published in Jan 2020, the Increasing number of travels to foreign countries and exposure to healthcare in countries with extensive C. Auris transmission and the higher flow of migrants can contribute to the quick dissemination of this species. Further, a higher frequency of C. Auris was found in public hospitals than private ones, which may be connected to overcrowding and compromised infection control measures. Thus, the factor is likely to boost the growth of the market.
Novartis AG, Sanofi, Pfizer Inc., Merck and Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., are among the prominent players present in the systemic aspergillosis and systemic candidasis market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in July 2018 Pfizer Inc. and Basilea Pharmaceutical Ltd. an international have entered into an agreement whereby Pfizer will be granted the exclusive commercialization rights in Europe to Cresemba a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients.
The report segments the South and Central America systemic aspergillosis and systemic candidasis market as follows:
- Systemic Oral Azoles
- Liposomal Amphotericin B
- Topical Antifungal Agents
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Chronic Pulmonary Aspergillosis (CPA)
- Gastrointestinal Candidiasis
- Genitourinary Tract Candidiasis
- Rest of South and Central America
Contact Person: Sameer Joshi
Email Id: email@example.com